PHARMA MAR, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.96 EUR | +0.49% |
|
+10.37% | -29.50% |
| Apr. 23 | Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 29 | Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024 |
Presenter SpeechJosé Martinez-Losa (Executives)Apologies about this trouble with our lines. An...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Companyâs product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
Sector
Pharmaceuticals
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
28.96
EUR
Average target price
49.2
EUR
Spread / Average Target
+69.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.50% | 545M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- PHM Stock
- News Pharma Mar, S.A.
- Transcript : Pharma Mar, S.A., H1 2023 Earnings Call, Jul 28, 2023
